GLP-1 receptor agonist effects on lipid and liver profiles in patients with nonalcoholic fatty liver disease: systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Aims. This meta‐analysis of randomized placebo‐controlled clinical trials assessed the effect of glucose‐like peptide‐1‐receptor agonists (GLP‐1RA) on the lipid profile and liver enzymes in patients with nonalcoholic fatty liver disease (NAFLD). Materials and Methods. Randomized placebo‐controlled trials investigating GLP‐1RA on the lipid profile and liver enzymes in patients with NAFLD were searched in PubMed‐Medline, Scopus, Web of Science, and Google Scholar databases (from inception to January 2020). A random‐effects model and a generic inverse variance method were used for quantitative data synthesis. Sensitivity analysis was conducted. Weighted random‐effects meta‐regression was performed on potential confounders on lipid profile and liver enzyme concentrations. Results. 12 studies were identified (12 GLP‐1RA arms; 677 subjects) that showed treatment with GLP‐1RA reduced alanine transaminase (ALT) concentrations (WMD = −10.14, 95%CI = [−15.84, −0.44], P < 0.001), gamma‐glutamyl transferase (GGT) (WMD = −11.53, 95%CI = [−15.21,−7.85], P < 0.001), and alaline phosphatase (ALP) (WMD = −8.29, 95%CI = [−11.34, −5.24], P < 0.001). Aspartate aminotransferase (AST) (WMD = −2.95, 95% CI = [−7.26, 1.37], P = 0.18) was unchanged. GLP‐1 therapy did not alter triglycerides (TC) (WMD = −7.07, 95%CI = [−17.51, 3.37], P = 0.18), total cholesterol (TC) (WMD = −1.17 (−5.25, 2.91), P = 0.57), high‐density lipoprotein (HDL‐C) (WMD = 0.97, 95%CI = [−1.63, 3.58], P = 0.46), or low‐density lipoprotein (LDL‐C) (WMD = −1.67, 95%CI = [−10.08, 6.74], P = 0.69) in comparison with controls. Conclusion. The results of this meta‐analysis suggest that GLP‐1RA treatment significantly reduces liver enzymes in patients with NAFLD, but the lipid profile is unaffected.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The effect of semaglutide and other single GLP-1RAs on triglycerides and HDL is generally modest,126 despite the significant weight loss, while it is better with tirzepatide.127”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305 · cited 1×
“*e overall evaluation of the evidence relating to the outcomes was conducted by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach (Table 2) [25].”
Cochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2009) · doi:10.1002/9780470743386 · Cited by 14,225
Cumpston, M., Li, T., Page, M. J., Chandler, J., Welch, V. A., Higgins, J. P., & Thomas, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.ed000142 · Cited by 7,218
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Vrabel, M. (2015) · Oncology Nursing Forum · doi:10.1188/15.onf.552-554 · Cited by 669
Wong, V. W., Chan, W., Chitturi, S., Chawla, Y., Dan, Y. Y., Duseja, A., Fan, J., Goh, K., Hamaguchi, M., Hashimoto, E., et al. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13857 · Cited by 506
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456
Capehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.101117 · Cited by 412
Araújo, A. R., Rosso, N., Bedogni, G., Tiribelli, C., & Bellentani, S. (2018) · Liver International · doi:10.1111/liv.13643 · Cited by 401
Younossi, Z. M., Loomba, R., Rinella, M. E., Bugianesi, E., Marchesini, G., Neuschwander‐Tetri, B. A., Serfaty, L., Negro, F., Caldwell, S. H., Ratziu, V., et al. (2018) · Hepatology · doi:10.1002/hep.29724 · Cited by 357
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2018) · Hepatology Communications · doi:10.1002/hep4.1124 · Cited by 309
Insulin Resistance, the Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease
Angelico, F., Del Ben, M., Conti, R., Francioso, S., Feole, K., Fiorello, S., Cavallo, M. G., Zalunardo, B., Lirussi, F., Alessandri, C., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1024 · Cited by 284
Yan, J., Yao, B., Kuang, H., Yang, X., Huang, Q., Hong, T., Li, Y., Dou, J., Yang, W., Qin, G., et al. (2019) · Hepatology · doi:10.1002/hep.30320 · Cited by 260
Yu, X., Hao, M., Liu, Y., Ma, X., Lin, W., Xu, Q., Zhou, H., Shao, N., & Kuang, H. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172715 · Cited by 190
Shao, N., Kuang, H. Y., Hao, M., Gao, X. Y., Lin, W. J., & Zou, W. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2561 · Cited by 185
Feng, W., Gao, C., Bi, Y., Wu, M., Li, P., Shen, S., Chen, W., Yin, T., & Zhu, D. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12555 · Cited by 164
Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys
Yaribeygi, H., Katsiki, N., Butler, A. E., & Sahebkar, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.08.005 · Cited by 140
Self-citationOhki, T., Isogawa, A., Iwamoto, M., Ohsugi, M., Yoshida, H., Toda, N., Tagawa, K., Omata, M., & Koike, K. (2012) · The Scientific World Journal · doi:10.1100/2012/496453 · Cited by 139
Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease
Fan, H., Pan, Q., Xu, Y., & Yang, X. (2013) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302013000900005 · Cited by 122 · cited 2×
“Seven studies used Liraglutide as an intervention [28, 30–35], and two others [26, 27, 29] used exenatide plus other treatments.”
Ranjbar, G., Mikhailidis, D. P., & Sahebkar, A. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154001 · Cited by 107
Self-citationMolecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity
Yaribeygi, H., Sathyapalan, T., & Sahebkar, A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116776 · Cited by 102
Self-citationKhoo, J., Hsiang, J., Taneja, R., Law, N., & Ang, T. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13007 · Cited by 99
Yaribeygi, H., Rashidy-Pour, A., Atkin, S. L., Jamialahmadi, T., & Sahebkar, A. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118645 · Cited by 96
Self-citationTian, F., Zheng, Z., Zhang, D., He, S., & Shen, J. (2018) · Bioscience Reports · doi:10.1042/bsr20181304 · Cited by 80
Kahal, H., Abouda, G., Rigby, A. S., Coady, A. M., Kilpatrick, E. S., & Atkin, S. L. (2014) · Clinical Endocrinology · doi:10.1111/cen.12369 · Cited by 79
Self-citationKahal, H., Aburima, A., Ungvari, T., Rigby, A. S., Coady, A. M., Vince, R. V., Ajjan, R. A., Kilpatrick, E. S., Naseem, K. M., & Atkin, S. L. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0005-6 · Cited by 74
Self-citationNeuromodulatory effects of anti-diabetes medications: A mechanistic review
Yaribeygi, H., Ashrafizadeh, M., Henney, N. C., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104611 · Cited by 69
Self-citationAntidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
Sumida, Y., Yoneda, M., Tokushige, K., Kawanaka, M., Fujii, H., Yoneda, M., Imajo, K., Takahashi, H., Eguchi, Y., Ono, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061907 · Cited by 68
Lv, X., Dong, Y., Hu, L., Lu, F., Zhou, C., & Qin, S. (2020) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.163 · Cited by 65
Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes
Yaribeygi, H., Maleki, M., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2019.117152 · Cited by 63
Self-citationZhu, W., Feng, P.-P., He, K., Li, S.-W., & Gong, J.-P. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.09.134 · Cited by 55
Yaribeygi, H., Farrokhi, F. R., Abdalla, M. A., Sathyapalan, T., Banach, M., Jamialahmadi, T., & Sahebkar, A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/6518221 · Cited by 31
Self-citationAntioxidative Potentials of Incretin‐Based Medications: A Review of Molecular Mechanisms
Yaribeygi, H., Maleki, M., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9959320 · Cited by 26
Self-citationThe role of incretins and incretin-based drugs in autoimmune diseases
Radbakhsh, S., Atkin, S. L., Simental‐Mendía, L. E., & Sahebkar, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107845 · Cited by 24
Self-citationEffect of liraglutide on lipids in patients with type 2 diabetes: a pilot study
Aoki, K., Kamiyama, H., Takihata, M., Taguri, M., Shibata, E., Shinoda, K., Yoshii, T., Nakajima, S., & Terauchi, Y. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej19-0464 · Cited by 16
Renoprotective Effects of Incretin‐Based Therapy in Diabetes Mellitus
Yaribeygi, H., Atkin, S. L., Montecucco, F., Jamialahmadi, T., & Sahebkar, A. (2021) · BioMed Research International · doi:10.1155/2021/8163153 · Cited by 14
Self-citationPioglitazone seems safe and effective for patients with fatty liver disease and diabetes
Wise, J. (2016) · BMJ · doi:10.1136/bmj.i3435 · Cited by 7
Schwenger, K. J. P. (2018) · TSpace (University of Toronto) · Cited by 2
Research works printed but not linked: 2
- WangD. J. J. M. U. Effect of exenatide combined with metformin therapy on insulin resistance liver function and inflammatory response in patients with type 2 diabetes mellitus combined with NAFLD Journal of Hainan Medical University 2017 23 no. 18 44–47.
- Khoo J., 2019, Comparing effects of liraglutide-induced weight loss versus lifestyle modification on liver fat content and plasma acylcarnitine levels in obese adults with nonalcoholic fatty liver disease, Obesity Facts, 12
Cited by
Pouwels, S., Sakran, N., Graham, Y., Leal, A., Pintar, T., Yang, W., Kassir, R., Singhal, R., Mahawar, K., & Ramnarain, D. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-00980-1 · Cited by 897
Lipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Reinson, T., Buchanan, R. M., & Byrne, C. D. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0348 · Cited by 75
Anti-inflammatory benefits of semaglutide: State of the art
Yaribeygi, H., Maleki, M., Jamialahmadi, T., & Sahebkar, A. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100340 · Cited by 72
Self-citationArvanitakis, K., Koufakis, T., Kotsa, K., & Germanidis, G. S. (2022) · Cancers · doi:10.3390/cancers14194651 · Cited by 63
Metadata
- Authors
- Rezaei, S., Tabrizi, R., Nowrouzi-Sohrabi, P., Jalali, M., Atkin, S. L., Al-Rasadi, K., Jamialahmadi, T., & Sahebkar, A.
- Affiliations
- Shiraz University (IR)
- Fasa University of Medical Sciences (IR)
- Shiraz University of Medical Sciences (IR)
- Weill Cornell Medical College in Qatar (QA)
- Mashhad University of Medical Sciences (IR)
- Corresponding author
- Sahebkar, Amirhossein
- ORCID
- Venue
- Canadian Journal of Gastroenterology and Hepatology
- Publisher
- Wiley
- Published
- 2021-01
- Volume
- 2021
- Issue
- 1
- Pages
- 8936865-8936865
- ISSN
- 2291-2789 (ISSN-L)
- 2291-2797
- PMC
- PMC8604595
- OpenAlex
- W3211702740
- Cited by
- 65
- References
- 43
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 17 · 2023: 9 · 2022: 11
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Canadian Journal of Gastroenterology and Hepatology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- GLP-1 receptor agonists, non-alcoholic fatty liver disease, lipid profile, liver enzymes, alanine aminotransferase, gamma-glutamyl transferase, aspartate aminotransferase, alkaline phosphatase, triglycerides, total cholesterol, HDL cholesterol, LDL cholesterol, LDL particle number, dyslipidemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Humans, Lipids, Triglycerides, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.